Biotest AG
↗Dreieich (Frankfurt), Germany
Biotest AG is a leading specialty pharmaceutical and biotherapeutics company headquartered in Dreieich (Frankfurt), Germany, founded in 1946. The company specializes in plasma-derived therapeutic products and is the world's market leader in hyperimmunoglobulins and the only manufacturer of IgM-enriched immunoglobulins. Operating across clinical immunology, hematology, and intensive care medicine, Biotest develops, manufactures, and distributes biological medicines with a state-of-the-art product portfolio ranging from preclinical to commercial stage. Since May 2022, Biotest has been a wholly-owned subsidiary of Grifols S.A., the Barcelona-based biopharmaceutical company, which completed acquisition of the remaining public shares in June 2025 followed by delisting from the Frankfurt Stock Exchange.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Plasma-derived therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$726.2M (2024)
Founded:1946
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Established / Post-IPO
Investors:Grifols S.A. (parent company, 99.25% stake)
STOCK
Exchange:Delisted June 2025
Ticker:BTTAY (previously traded on NASDAQ ADR), BIO3 (Xetra), BIO.DE (Frankfurt - delisted)
PIPELINE
Stage:Phase 3/Commercial
Lead Drug Stage:Commercial (Yimmugo approved); Phase 3 (Fibrinogen, Trimodulin)
Modalities:Plasma-derived immunoglobulins, Coagulation factors, Albumin, Polyvalent antibodies
Active Trials:3
Trial Phases:Phase 3: 3
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Grifols S.A.
Acquired By:Grifols S.A. (2022-05-01)
Subsidiaries:Biotest subsidiary operations in Austria, Biotest subsidiary operations in Switzerland, Biotest subsidiary operations in France, Biotest subsidiary operations in Great Britain, Biotest subsidiary operations in Italy, Biotest subsidiary operations in Hungary, Biotest subsidiary operations in Spain, Biotest subsidiary operations in Brazil
Key Partnerships:Kedrion: Exclusive 7-year distribution agreement for Yimmugo in the United States (2024-2031)
COMPETITION
Position:Leader
Competitors:Kedrion Biopharma, CSL Behring, Octapharma, Baxter International, Bristol Myers Squibb
LEADERSHIP
Key Executives:
Dr. Jörg Schüttrumpf - Chief Executive Officer
Dr. Michael Ramroth - Chairman and Chief Financial Officer (until end of contract)
Martin Möller - Chief Financial Officer
Ainhoa Mendizabal - Chief Financial Officer
Board Members:Dirk Schuck (Member, Supervisory Board), Raimon Grifols Roura (Member, Supervisory Board), Prof Dr Gernot Hebestreit (Member, Supervisory Board; Chairman of Audit Committee)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Biotest AG and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Biotest AG. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.